Long-Term Outcomes of SGLT2 Inhibitors in Heart Failure: Meta-Analysis of Landmark Trials

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as a cornerstone therapy for heart failure (HF), demonstrating robust benefits across preserved and reduced ejection fraction phenotypes. Initially developed as antidiabetic agents, SGLT2 inhibitors have shown cardio-renal protective effects independent of glycemic control, yet questions remain regarding their long-term impact on clinical outcomes. A comprehensive evaluation of long-term efficacy and safety across landmark trials is essential to inform treatment guidelines and optimize chronic HF management. Methods and Results: This meta-analysis pooled data from seven major randomized controlled trials—DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, SOLOIST-WHF, DELIVER, DEFINE-HF, and PRESERVED-HF—encompassing over 48,000 patients with heart failure across the ejection fraction spectrum. The primary endpoint was a composite of cardiovascular death or hospitalization for HF, with secondary outcomes including all-cause mortality, renal function decline, and quality-of-life metrics. At a median follow-up of 24 months, SGLT2 inhibitors significantly reduced the risk of the primary endpoint by 23%, with consistent benefit in both HFrEF and HFpEF subgroups. All-cause mortality was reduced by 14%, and progression to end-stage renal disease was attenuated by 28%. The incidence of adverse events, including volume depletion, hypoglycemia, and genitourinary infections, remained low and manageable. Subgroup analyses showed enhanced benefit in patients with diabetes, chronic kidney disease, and elevated natriuretic peptides. Conclusion: Long-term use of SGLT2 inhibitors confers substantial and sustained reductions in morbidity and mortality in patients with heart failure, regardless of ejection fraction. These findings support broad implementation of SGLT2 inhibitors as foundational therapy in HF management and underscore their role in integrated cardio-renal-metabolic care.